What to expect from Amgen's Q4 earnings?
Amgen (NASDAQ:AMGN) is scheduled to announce Q4 earnings results on Tuesday, January 31st, after market close.
The consensus EPS Estimate is $4.09 and the consensus Revenue Estimate is $6.77B
Over the last 2 years, AMGN has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time.

Over the last 3 months, EPS estimates have seen 7 upward revisions and 9 downward. Revenue estimates have seen 9 upward revisions and 6 downward.

Amgen revised its full-year revenue and EPS guidance last quarter and now expects to be $26B-$26.3B from a prior outlook of $25.5-$26.4B vs $26.25B consensus.

Last month, the company said it would buy rare-disease-focused Horizon Therapeutics for $116.50 per share in cash, valuing the Ireland-based biotech at nearly $27.8B, in its biggest-ever acquisition.

Earlier today, Biotech giant Amgen laid off 300 workers, mostly from its commercial team, Endpoints News reported.

Also Read - Amgen: Dividend Growth Secure But Keep An Eye On Debt, Margins